Document:

Exhibit 4.2

 

Form
of Note

 

NEITHER
THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

 

CONVERTIBLE
NOTE

 

	Issuance
    Date: ____________ __, 2021	Original
    Principal Amount: $_____________
	Note
    No. __	 

 

FOR
VALUE RECEIVED, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Shuttle Pharma” or the “Maker”),
hereby promises to pay to the order of _________________________ (the “Subscriber”), or registered assigns (together
with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant
to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the
Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay
interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as
the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration,
conversion, redemption or otherwise (in each case in accordance with the terms hereof).

 

The
Original Principal Amount is _________________________ Dollars ($__________). For purposes hereof, the term “Outstanding Balance”
means the Original Principal Amount, as reduced or increased, as the case may be, pursuant to the terms hereof for conversion, breach
hereof or otherwise, plus any accrued but unpaid interest, collection and enforcements costs, and any other fees or charges incurred
under this Note provided that, in the event of an optional or mandatory conversion of the Note into
shares of Common Stock (as provided herein), all accrued interest on the Principal subject to such conversion shall be waived.

 

This
Note is being issued pursuant to the terms of a subscription agreement dated as of ____ __, 2021 between the Maker and the Subscriber
and exhibits thereto (collectively, the “Transaction Documents”). Unless otherwise defined herein, all capitalized
terms, when used in this Note, shall have the same meaning as they are defined in the Transaction Documents.

 

1. GENERAL
TERMS

 

(a) Payment
of Principal. Unless previously converted into shares of the common stock, $0.00001par value, of Shuttle Pharma or the common stock
of any successor in interest to the Maker (each the “Common Stock”) as contemplated hereby, this Note, together with
all accrued interest hereon at the Interest Rate, shall be due and payable on December 31, 2024 (the “Maturity Date”).
In the event that within 12 months of the Issuance Date, the Maker shall not have consummated an initial public offering of its Common
Stock and the listing or trading of its Common Stock on a “Qualified Securities Market”, as defined below (the “IPO”)
or other “Liquidity Event” (hereinafter defined), the Maker may elect either (a) up on thirty (30) days prior written
notice to the Holder, elect to prepay all of the principal amount of the Note and accrued interest hereon, subject to the Holder’s
right to convert the Note into Common Stock during such thirty (30) day period, or (b) if the Maker does not prepay the entire principal
amount of the Note or the remaining principal amount of the Note, this Note will automatically increase to 110% of the original or unpaid
portion of the outstanding principal amount.

 

    	 

     

    

 

(b) Interest.
Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of six
percent (6%) (the “Interest Rate”) and all accrued interest shall be fully paid on the Maturity Date (or sooner as
provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration
and transfers of Notes in cash. However, in the event of an optional or mandatory conversion of the Note into shares of Common Stock
(as provided herein), all accrued interest on the Principal subject to such conversion shall be waived.

 

2. EVENTS
OF DEFAULT.

 

Whenever
used herein, an “Event of Default” means the occurrence and continuation of any one of the following events, whatever
the reason, and whether it shall be voluntary or involuntary, or effected by operation of law or pursuant to any judgment, decree or
order of any court, or any order, rule or regulation of any administrative or governmental body:

 

(a) The
Maker’s failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this Note; or

 

(b) A
Conversion Failure as defined in Section 3(d)(ii); or

 

(c) A
material breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Transaction Documents or a material
breach by Shuttle Pharma of any material representation, warranty or covenant contained in the Purchase Agreement, that, if capable of
cure, is not cured within 30 days from the date such breach has occurred; or

 

(d) The
Maker or any subsidiary of the Maker shall commence, or there shall be commenced against the Maker or any subsidiary of the Maker under
any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Maker or any subsidiary of
the Maker commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency
or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Maker or any subsidiary of the Maker
or there is commenced against the Maker or any subsidiary of the Maker any such bankruptcy, insolvency or other proceeding which remains
undismissed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker is adjudicated insolvent or bankrupt; or
any order of relief or other order approving any such case or proceeding is entered; or the Maker or any subsidiary of the Maker suffers
any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of its property which
continues undischarged or unstayed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker makes a general
assignment for the benefit of creditors; or the Maker or any subsidiary of the Maker shall fail to pay, or shall state that it is unable
to pay, or shall be unable to pay, its debts generally as they become due; or the Maker or any subsidiary of the Maker shall call a meeting
of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Maker or any subsidiary of
the Maker shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing;
or any corporate or other action is taken by the Maker or any subsidiary of the Maker for the purpose of effecting any of the foregoing.

 

3. CONVERSION
OF NOTE. This Note shall be convertible into shares of Common Stock, on the terms and conditions set forth in this Section 3.

 

(a) Certain
Definitions. As used in this Note, the following capitalized terms shall have the meaning set forth below:

 

(i) “Alternative
Liquidity Event” shall mean any one of a Sale of Control, a SPAC Acquisition, or a Reverse Merger.

 

    	 

     

    

 

(ii)
“Alternative Liquidity Event Conversion Price” shall mean a conversion price that is equal to 50% of the
aggregate “Transaction Consideration” (as defined) divided by the total number of outstanding shares of common stock of
the acquiror resulting from a Sale of Control, the merger with a SPAC or the successor in interest “Pubco” (as
defined) in connection with a Reverse Merger.

 

(iii) “Common
Stock” shall mean, as applicable, the individual or collective reference to the Common stock, $0.00001 par value per share,
of the Maker or the common stock of any acquiror in a Sale of Control, SPAC or Pubco resulting from a Sale of Control, SPAC Acquisition
or Reverse Merger.

 

(iv) “Conversion
Shares” shall mean the aggregate number of shares of Common Stock of the Maker, the Acquiror in a Sale of Control the SPAC
or Pubco, as applicable (each an “Issuer”) that are issuable to the Holder in connection with any mandatory conversion
(set forth in Section 3(b)) or optional conversion (set forth in Section 3(c)) of this Note.

 

(v) “IPO”
shall mean an initial public offering of Common Stock of the Maker pursuant to a registration statement on Form S-1 that is declared
effective by the Securities and Exchange Commission.

 

(vi) “IPO
Conversion Price” shall mean a conversion price equal to 50% of the initial public offering price per share of the Common Stock
offered to the public in the IPO.

 

(vii) “Liquidity
Event” shall mean any one of an IPO, a Sale of Control, a SPAC Acquisition or a Reverse Merger.

 

(viii)
“Optional Conversion Price” shall mean a conversion price that is equal to the price per share determined by dividing
$50 million by the total number of outstanding shares of Common Stock of the Maker.

 

(ix) “Pre-Money
Valuation” shall mean the dollar value placed on the total number of outstanding shares of Common Stock and Preferred Stock
of the Company immediately prior to a Liquidity Event.

 

(x) “Preferred
Stock” means the Series A convertible preferred stock, par value $0.00001 per share, of the Company, of which there are 1,212.5
shares outstanding.

 

(xi) “Pubco”
means a fully-reporting public corporation under the Securities Exchange Act of 1934, as amended, that does not have any significant
business activities and is trading on Nasdaq or the OTCQX platform of the OTC Market.

 

(xii) “Qualified
Securities Market” shall mean any one of the Nasdaq Stock Exchange (including the Nasdaq Capital Market), the NYSE:Amex Exchange,
the New York Stock Exchange or the OTCQX platform of the OTC Markets.

 

(xiii) “Reverse
Merger” means a merger of the Maker with or the acquisition of the Maker by Pubco, as a result of which such transaction, the
stockholders of the Maker will own a substantial majority of the equity securities of Pubco.

 

(xiv)
“Sale of Control” shall mean a sale of all or substantially as of the capital stock or assets of the Company to any
unaffiliated third Person, whether through share sale, asset sale, merger, consolidation or like combination, as a result of which the
ability to control the board of directors of the Company shall pass to such third Person.

 

    	 

     

    

 

(xv) “SPAC”
means a special purpose acquisition corporation whose securities are listed on Nasdaq or the New York Stock Exchange.

 

(xvi) “SPAC
Acquisition” means a merger of the Maker with or the acquisition of the Maker by a SPAC or its subsidiary, as a result of which
such transaction, the stockholders of the Maker will own a majority of the equity securities of the SPAC.

 

(xvii) “Transaction
Consideration” shall mean the dollar value placed on the total consideration paid to the Company including, but not limited
to, (i) the value of the Transaction, including consideration whether in cash, stock or in-kind, received by and/or paid by the Company,
(ii) the total amount of indebtedness for borrowed funds, capitalized lease obligations and non-trade liabilities of the Company that
are either assumed by the acquirer, redeemed or otherwise satisfied in connection with the transaction, or which remain outstanding after
the transaction is consummated; (iii) the fair market value of any assets excluded from the transaction; (iv) the fair market value of
any ownership interests which are retained by the Company’s shareholders or which remain outstanding after the transaction is consummated;
and (v) the amount of any contingent payments, including, without limitation, earn-outs and future royalties payable in connection with
the transaction.

 

(b) Mandatory
Conversion. In the event that prior to the Maturity Date of this Note, the Maker shall consummate an IPO and its Common Stock shall
be approved for listing or trading on any Qualified Securities Market, the entire Outstanding Balance of this Note shall automatically,
and without any further consent or approval of the Holder, be converted into Common Stock of the Maker at the IPO Conversion Price. In
the event that prior to the Maturity Date, the Maker shall consummate an Alternative Liquidity Event, the Holder may elect at his or
its option to convert the outstanding and unpaid Outstanding Balance of this Note into Common Stock of the Maker at the Alternative Liquidity
Event Conversion Price. The IPO Conversion Price and the Alternative Liquidity Event Conversion Price (either, the “Mandatory
Conversion Price”) shall be subject to adjustment, as provided for in Section 3(f) below.

 

(c) Optional
Conversion. At any time, at the Holder’s option, such Holder may convert the outstanding and unpaid Outstanding Balance of
this Note into fully paid and nonassessable shares of Common Stock in accordance with this Section 3(c), at the Optional Conversion
Price, subject to adjustment as provided in Section 3(f) below. If the issuance would result in the issuance of a fraction of
a share of Common Stock, Shuttle Pharma shall round such fraction of a share of Common Stock up to the nearest whole share. Shuttle Pharma
shall pay any and all transfer agent fees, legal fees, costs and any other fees or costs that may be incurred or charged in connection
with the issuance and legend removal of shares of Common Stock to the Holder arising out of or relating to the conversion of this Note
up to a maximum of five thousand dollars ($5,000).

 

(d) Mechanics
of Conversion.

 

(i) Optional
Conversion. To convert the Note pursuant to an optional conversion into shares of Common Stock on any date (a “Conversion
Date”), the Holder shall (A) transmit by email, facsimile (or otherwise deliver), for receipt on or prior to 11:59 p.m., New
York, NY Time, a copy of an executed notice of conversion in the form attached hereto as Exhibit A (the “Conversion Notice”)
to Shuttle Pharma. On or before the tenth (10th) Business Day following the date of receipt of a Conversion Notice (the “Share
Delivery Date”), Shuttle Pharma shall (A) if legends are not required to be placed on certificates of Common Stock pursuant
to the then existing provisions of Rule 144 of the Securities Act of 1933 (“Rule 144”) and provided that the Transfer
Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, credit
such aggregate number of shares of Common Stock to which the Holder shall be entitled to the Holder’s or its designee’s balance
account with DTC through its Deposit Withdrawal Agent Commission system or (B) if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, issue and deliver to the address as specified in the Conversion Notice, a certificate, registered
in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled which certificates
shall not bear any restrictive legends unless required pursuant the Rule 144. The Person or Persons entitled to receive the shares of
Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such shares
of Common Stock upon the transmission of a Conversion Notice.

 

    	 

     

    

 

(ii) Issuer’s
Failure to Timely Convert. If within ten (10) business days after a Liquidity Event or (in the case of an optional conversion) Shuttle
Pharma receipt of the facsimile or email copy of a Conversion Notice together with documentation satisfactory to the Transfer Agent that
the Conversion Shares are eligible for such electronic issuance, the Issuer shall fail to issue and deliver to Holder via “DWAC/FAST”
electronic transfer (assuming that such shares are “DWAC/FAST” eligible) the number of Conversion Shares to which the Holder
is entitled upon such holder’s conversion of any Conversion Shares (a “Conversion Failure”), the Outstanding
Balance of the Note shall increase by 0.05% per day until such time as the Issuer of the Conversion Shares issues and delivers a certificate
to the Holder or credit the Holder’s balance account with DTC for the number of Conversion Shares to which the Holder is entitled
upon such mandatory or optional conversion. The Issuer of the Conversion Shares will not be subject to any penalties once its transfer
agent processes the shares to the DWAC system. If the issuer fails to deliver shares in accordance with the timeframe stated in this
Section, resulting in a Conversion Failure, the Holder, at any time prior to selling all of those Conversion Shares, may rescind any
portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount
returned to the Outstanding Balance with the rescinded Conversion Shares returned to the applicable Issuer.

 

(iii) Book-Entry.
Notwithstanding anything to the contrary set forth herein, in connection with any optional or mandatory conversion of this Note in accordance
with the terms hereof, the Holder shall not be required to physically surrender this Note to Shuttle Pharma unless and until such time
as the Holder has converted his or her shares in full. Upon a partial or full conversion, Holder shall receive either (i) one or more
stock certificates, or a book entry account statement, evidencing the Conversion Shares (in the event Shuttle Pharma’s Common Stock
is not yet DTC eligible) or (ii) physical evidence from the Issuer’s transfer agent that the Holder’s balance account with
DTC showing that the Conversion Shares have been credited for the number of Conversion Shares to which the Holder is entitled upon such
mandatory or optional conversion. The Holder and the Issuer shall maintain records showing the Outstanding Balance converted and the
dates of such conversions or shall use such other method reasonably satisfactory to the Holder and Issuer, so as not to require physical
surrender of this Note upon conversion, unless so requested by Shuttle Pharma.

 

(e) Limitations
on Conversions or Trading.

 

If
at any time after the Closing, the Holder shall or would receive Conversion Shares or shall purchase additional shares of Common Stock
of an Issuer, so that the Holder would, together with other shares of Common Stock held by it or its Affiliates, own or beneficially
own by virtue of such action or receipt of additional shares of Common Stock a number of shares exceeding 9.99% of the number of shares
of Common Stock outstanding on such date (the “Maximum Percentage”), the Issuer shall not be obligated and shall not
issue to the Holder Conversion Shares which would exceed the Maximum Percentage, but only until such time as the Maximum Percentage would
no longer be exceeded by any such receipt of shares of Common Stock by the Holder. Upon delivery of a written notice to the applicable
Issuer the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after delivery of
such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided
that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered
to Shuttle Pharma and (ii) any such increase or decrease will apply only to the Holder and its Affiliates. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(e) to the extent
necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial
ownership limitation contained in this Section 3(e) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of the
Note.

 

(f) Adjustment
of Conversion Price. In the event that a Liquidity Event prior to the December 31, 2024 Maturity Date of this Note, the Maker shall
raise additional capital through a private placement of Common Stock or other securities that are convertible or exercisable for Common
Stock, in either case, at a price less than the Optional Conversion Price, then and in such event the Conversion Price of the Notes shall
be adjusted to reflect such lower amount.

 

    	 

     

    

 

(g) Other
Provisions.

 

(i) Share
Reservation. Shuttle Pharma shall at all times reserve and keep available out of its authorized Common Stock a number of shares equal
to at least the full number of shares of Common Stock issuable upon conversion of all outstanding amounts under this Note.

 

(ii)
Prepayment. This Note may not be prepaid by Shuttle Pharma until March 31, 2022. Thereafter, the Note may either be prepaid by
the Company in whole or in part without penalty, fees or premium upon not less than twenty (20) business days prior written notice to
the Holder (the “Prepayment Notice”) which shall set forth the date on which the Note shall be prepaid (the “Prepayment
Date”), subject to the Holder’s right to convert all or any portion of this Note into Conversion Shares at the Optional
Conversion Price prior to the Prepayment Date.

 

(iii) All
calculations under this Section 3 shall be rounded up to the nearest whole share.

 

(iv) Nothing
herein shall limit a Holder’s right to pursue actual damages or declare an Event of Default pursuant to Section 2 herein for Shuttle
Pharma’s failure to deliver certificates or credit entries representing shares of Common Stock upon conversion within the period
specified herein and such Holder shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief, in each case without the need to post a bond or provide other security. The
exercise of any such rights shall not prohibit the Holder from seeking to enforce damages pursuant to any other Section hereof or under
applicable law.

 

(v) The
Maker shall use its best efforts to assist the Holder to obtain a legal opinion for the removal of any restrict legend in connection
with any shares converted from this Note.

 

(vi) This
Note is one of the Convertible Notes issued on or about the date of this Note by the Maker in an aggregate principal amount of up to
$2,000,000, (the “Notes”). Each of the Notes shall rank equally without preference or priority of any kind over one
another, and all payments and recoveries under the Notes payable on account of principal and interest on the Notes shall be paid and
applied ratably and proportionately on the balance of all outstanding Notes on the basis of their original principal amount.

 

4. REISSUANCE
OF THIS NOTE.

 

Upon
receipt by the Maker of evidence reasonably satisfactory to the Maker of the loss, theft, destruction or mutilation of this Note, and,
in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Maker in customary form and, in the
case of mutilation, upon surrender and cancellation of this Note, the Maker shall execute and deliver to the Holder a new Note representing
the outstanding Principal.

 

5.
NOTICES. Any notices, consents, waivers or other communications required or permitted to be given under the terms shall be handled
according to the Notice clause in the Subscription Agreement.

 

The
addresses for such communications shall be:

 

If
to the Maker:

Dr.
Anatoly Dritschilo, CEO

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville,
MD 20850

Email:
[ ]@shuttlepharma.com

 

If
to the Holder:

 

    	 

     

    

 

6.
APPLICABLE LAW AND VENUE. This Note shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to conflicts of laws thereof. Any action brought by either party against the other concerning the transactions
contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in New York
County, in the State of New York. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of
such courts.

 

7. WAIVER.
Any waiver by the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach
of such provision or of any breach of any other provision of this Note. The failure of the Holder to insist upon strict adherence to
any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist
upon strict adherence to that term or any other term of this Note. Any waiver must be in writing.

 

8. MISCELLANEOUS

 

(a) Lawful
Money; Costs of Collection. All amounts payable hereunder are payable in lawful money of the United States. Shuttle Pharma agrees
to pay all costs of collection when incurred, including reasonable attorneys’ fees and costs, whether or not a suit or action is
instituted to enforce this Note, including but not limited to court costs, appraisal fees, the cost of searching records, obtaining title
reports and title insurance and trustee’s fees, to the extent permitted by applicable law.

 

(b) No
Offset; Holder in Due Course. All payments under this Note made by or on behalf of Shuttle Pharma shall be made without setoff or
counterclaim and free and clear of, and without deduction or withholding for or on account of, any federal, state, or local taxes. Shuttle
Pharma waives any right of offset it now has or may hereafter have against Agent or Holder and its successors and assigns as to this
Note (but retains any such rights as to any other prior or future transaction between these parties), and agrees to make the payments
called for hereunder in accordance with the terms hereof. The holder hereof and all successors thereof shall have all the rights of a
holder in due course as provided in the Delaware Uniform Commercial Code and other laws of the State of Delaware.

 

(c) Waivers.
Shuttle Pharma and any endorsers, guarantors or sureties hereof severally waive presentment and demand for payment, notice of intent
to accelerate maturity, protest or notice of protest or non-payment, bringing of suit and diligence in taking any action to collect
any sums owing hereunder or in proceeding against any of the rights and properties securing payment hereunder; expressly agree that
this Note, or any payment hereunder, may be extended from time to time; and consent to the acceptance of further security or the
release of any security for this Note, all without in any way affecting the liability of Shuttle Pharma and any endorsers or
guarantors hereof. No extension of time for the payment of this Note, or any installment hereof, made by agreement by the holder
hereof with any person now or hereafter liable for the payment of this Note, shall affect the original liability under this Note of
Shuttle Pharma, even if Shuttle Pharma (or any entity comprising Shuttle Pharma) is not a party to such agreement.

 

(d) Usury
Protection. The parties hereto intend to conform strictly to the applicable usury laws. In no event, regardless of any provisions
contained therein or in any other document executed or delivered in connection herewith, shall the holder hereof ever be deemed to have
contracted for or be entitled to receive, collect or apply as interest on this Note, any amount in excess of the maximum amount permitted
by applicable law (the “Maximum Rate”). In no event, whether by reason of demand for payment, prepayment, acceleration
of the maturity hereof or otherwise, shall the interest contracted for, charged or received by the holder hereunder or otherwise exceed
the Maximum Rate. If for any circumstance whatsoever interest would otherwise be payable to the holder in excess of the maximum lawful
amount, the interest payable to the holder shall be reduced automatically to the Maximum Rate and any payment received in excess of such
amount shall be applied to the outstanding principal balance of the Note.

 

(e) Entire
Agreement. This Note, the other Transaction Documents, and all other documents and instruments contemplated hereby and thereby together
constitute the entire agreement between and among the parties pertaining to the subject matter hereof. No supplement, modification or
amendment of this Note shall be binding unless executed in writing by the parties. No waiver shall be binding unless executed in writing
by the party making the waiver. No provision of this Note shall be interpreted for or against the drafting party.

 

    	 

     

    

 

(f) Commercial
Purpose. Shuttle Pharma agrees that no funds advanced under this Note shall be used for personal, family or household purposes, and
that all funds advanced hereunder shall be used solely for business, commercial, investment or other similar purposes.

 

(g) Successors
and Assigns. All the terms and provisions of this Note shall be binding upon and inure to the benefit of the parties to this Note
and their respective successors and assigns.

 

(h) Assignment.
Shuttle Pharma may not, voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise, sell, transfer, assign,
hypothecate, pledge or in any way alienate this Note or any right or interest in this Note (each a “Transfer”) without
Holder’s prior written consent, which Holder may withhold in its sole and absolute discretion. Any consent by Holder to any Transfer
shall not constitute consent to any other Transfer. Holder may freely Transfer its interest, rights, or title in or to this Note or the
other Transaction Documents in Holder’s sole and absolute discretion.

 

(i) Construction.
Whenever used in this Note, the terms “including,” “include,” “includes” and the like are not
intended as terms of limitation, and, hence, shall be deemed to be followed by “without limitation.”

 

(j) Severability.
If any provision of this Note, as applied to any party or to any circumstance, shall be found by a court of competent jurisdiction to
be void, invalid or unenforceable, the same shall in no way affect any other provision of this Note, the application of any such provision
in any other circumstance, or the validity or enforceability of this Note, and any provision which is found to be void, invalid or unenforceable
shall be curtailed and limited only to the extent necessary to bring such provision within the requirements of the law.

 

(k) Survival
of Terms. The terms and provisions of this Note shall survive the Maturity Date until full payment of all amounts due hereunder.

 

(l) Preferential
Payment. If at any time any payment made pursuant to this Note is deemed to have been a voidable preference, fraudulent conveyance
or other similar conveyance or preferential payment under any bankruptcy, insolvency or other debtor relief or similar law, then the
obligation to make such payment shall survive any cancellation or satisfaction of this Note or return of this Note to Shuttle Pharma
and shall not be discharged or satisfied with any such payment or cancellation. Such payment shall instead remain a valid and binding
obligation enforceable in accordance with the terms of this Note and shall be immediately due and payable.

 

(m) Relief
From Stay. As an additional inducement to and material consideration for Holder agreeing to execute this this Note and the other
Transaction Documents, Shuttle Pharma agrees that in the event a Bankruptcy or Judicial Action (as hereinafter defined in this Section
8(n)) is commenced which subjects Holder to any stay in the exercise of Holder’s rights and remedies under this Note or the
other Transaction Documents, including, but not limited to, the automatic stay imposed by Section 362 of the United States Bankruptcy
Code (individually and collectively, “Stay”), then Shuttle Pharma irrevocably consents and agrees that such Stay shall
automatically be lifted and released against Holder, and Holder shall thereafter be entitled to exercise all of its rights and remedies
against Shuttle Pharma that is or could be subject any Stay under this Note or the other Transaction Documents. Nothing contained herein
shall limit or prevent Holder from exercising all of its rights and remedies against Shuttle Pharma that is not the subject any Stay
under this Note or the other Transaction Documents. Shuttle Pharma acknowledges that it is knowingly, voluntarily, and intentionally
waiving its rights to any Stay and agrees that the benefits provided to Shuttle Pharma under the terms of this Note are valuable consideration
for such waiver. As used in this Section 8(n), the term “Bankruptcy or Judicial Action” shall mean any voluntary
or involuntary case filed by or against a Shuttle Pharma under the United States Bankruptcy Code, or any voluntary or involuntary petition
in composition, readjustment, liquidation, or dissolution, or any state and federal bankruptcy law action filed by or against a Shuttle
Pharma, any action where a Shuttle Pharma is adjudicated as bankrupt or insolvent, any action for dissolution of a Shuttle Pharma, or
any action in furtherance of any of the foregoing, or any other action, case, or proceeding that has the effect of staying (or in which
a stay is being obtained against) the enforcement by Holder of its rights and remedies under the this Note or the other Transaction Documents.

 

    	 

     

    

 

Except
to enforce the terms of the Transaction Documents, Shuttle Pharma shall not take any action and shall not fail to take any action which
such action or omission will or might tend to interfere with, delay, enjoin or otherwise prohibit the commencement, continuation or completion
of efforts by Holder to enforce its remedies under this Note or the other Transaction Documents, or applicable law. Without limiting
the generality of the foregoing and except to enforce the terms of the Transaction Documents, each Shuttle Pharma waives its, his, or
her rights, if any, to seek or obtain a stay, injunction or other form of order prohibiting in any way any act necessary or appropriate
for the commencement or completion of Holder’s enforcement of its remedies under the this Note or the other Transaction Documents,
or applicable law (without limiting the generality of the foregoing, such waiver extends to such rights which may exist under any statute
or rule relating to bankruptcy cases, including, without limitation, 11 U.S.C. § 105, 11 U.S.C. § 301, 11 U.S.C. § 302,
11 U.S.C. § 303, 11 U.S.C. § 304, 11 U.S.C. § 362, 11 U.S.C. § 348, 11 U.S.C. § 706, 28 U.S.C. § 157, 28
U.S.C. § 158, Federal Rule of bankruptcy Procedure (“FRBP”) 3007, FRBP 3008, FRBP 3012, FRBP 8005, FRBP 9023, FRBP 9024,
or FRBP 9029).

 

9. AMENDMENT
AND WAIVER OF RIGHTS. This Note may be amended and the observance of any term hereof may be waived (either generally or in a particular
instance either retroactively or prospectively) only by a written instrument executed by the Maker and the Holder.

 

10. WAIVER
OF RIGHT TO TRIAL BY JURY.

 

EACH
PARTY TO THIS NOTE HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (1) ARISING UNDER
THIS NOTE, THE OTHER TRANSACTION DOCUMENTS, OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH,
OR (2) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS NOTE
OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO,
IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY
AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY. THE PARTIES
HERETO HEREBY AGREE THAT THE PROVISIONS CONTAINED HEREIN HAVE BEEN FAIRLY NEGOTIATED ON AN ARM’S-LENGTH BASIS, WITH BOTH SIDES
AGREEING TO THE SAME KNOWINGLY AND BEING AFFORDED THE OPPORTUNITY TO HAVE THEIR RESPECTIVE LEGAL COUNSEL CONSENT TO THE MATTERS CONTAINED
HEREIN. ANY PARTY TO THIS NOTE MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT
OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY AND THE AGREEMENTS CONTAINED HEREIN REGARDING THE APPLICATION OF
JUDICIAL REFERENCE IN THE EVENT OF THE INVALIDITY OF SUCH JURY TRIAL WAIVER.

 

IN
WITNESS WHEREOF, each of the Maker has caused this Note to be duly executed by a duly authorized officer as of the date set forth above.

 

	 	Shuttle
    Pharmaceuticals Holdings, Inc.
	 	 
	 	By:	
	 	Name:	Dr.
    Anatoly Dritschilo
	 	Title:	Chief
    Executive Officer

 

Note
No. [   ]

 

    	 

     

    

 

EXHIBIT
A

 

NOTICE
OF CONVERSION

 

Shuttle
Pharmaceuticals Holdings, Inc.

One
Research Court, Suite 450

Rockville,
MD 20850

Email:
[      ]@shuttlepharma.com

 

The
undersigned hereby elects to convert $[     ] of the $[     ] Convertible Note (Note No. [     ]) issued to [                    ] on [     ], 2021 into Shares of Common
Stock of Shuttle Pharmaceuticals Holdings, Inc. according to the conditions set forth in such Note as of the date written below.

 

If
the number of shares to be delivered represents more than 4.99% of the common stock outstanding, this conversion notice shall immediately
automatically extinguish and Holder must be immediately notified.

 

	Date
    of Conversion:	 
	Optional
    Conversion Amount:	 
	Conversion
    Price:	 
	Shares
    to be Delivered:	 
	Shares
    delivered in name of:	 

 

	 	HOLDER
	 	 
	 	[      ]
	 	 	 
	 	By:	
	 	 	     
	 	Title:Exhibit
10.5

 

EMPLOYMENT
AGREEMENT

 

This
contract of employment is made this 30th day of July, 2014 between Shuttle Pharmaceuticals, LLC (hereinafter “Company”),
and Theodore L. Phillips, M.D. (hereinafter “Employee”).

 

The
terms of employment as set out herein will be deemed to constitute a contract of employment (hereinafter “Agreement”). Employee
will be required to sign at the space provided at the end of these conditions, agreeing to adhere to the Company’s conditions of
employment.

 

1.
Employment & Duties, Duration, Termination

 

1.1
Employment & Duties. The Employee agrees that he will at all times faithfully, industriously, and to the best of his skill,
ability, experience and talents, perform all of the duties required of his position as “Director, Clinical Development” for
the Company at 51% effort employment, which duties include, but are not limited to: (a) Perform clinical drug development of novel chemical
entities for the Company’s drug discovery/development program; (b) Serve as Principal Investigator of the Fast-Track SBIR grant
and service as principal investigator, as needed, on other SBIR grant application submissions. In carrying out these duties and responsibilities,
the Employee shall comply with all Company policies, procedures, rules and regulations, both written and oral, as are announced by the
Employer from time to time. It is also understood and agreed to by the Employee that his assignment, duties and responsibilities and
reporting arrangements may be changed by the Company in its sole discretion.

 

 1.2 Date of Employment Commencement. September 15, 2014. 

 

1.3
Employment Duration. The employment term/duration shall be “at will” of either party. Nothing in Employer’s
policies, actions, or this document shall be construed to alter the “at will” nature of Employee’s status with Employer.

 

1.4
Annual Performance Review. The Employee will be provided a written performance appraisal at least once a year.

 

1.5
Termination. Employee understands that Employer may terminate his/her employment at any time for any reason or for no reason,
provided it is not terminated in violation of state or federal law.

 

2.
Compensation and Benefits

 

2.1
Salary. As compensation for all services to be rendered pursuant to this Agreement, Company agrees to pay Employee a base salary
at the rate of one hundred eighty thousand dollars ($181,500.00) per annum which will be pro-rated to 51% effort, based on percent effort
on NIH SBIR contracts. The salary set forth herein shall be payable in accordance with the regular payroll practices of the Company.

 

2.2
Bonus. Employee shall be eligible to participate in the company sponsored stock options program. 

 

2.2
Health Benefits. The Company shall not provide the Employee with health plan benefits.

 

2.3
Leave. In addition to approved public holidays, the Employee shall be entitled to paid leave in the amount of two weeks per calendar
year.

 

3.
Conflicts With Other Activities

 

During
employment with Company, Employee agrees that he will not, without prior written notice to Company, engage in any employment or business
performing similar drug discovery or development work.

 

    	1

     

    

 

4.
Protection of Confidential Information and Ownership of Inventions

 

4.1
Confidential Information Defined. The Company is engaged in the business of developing novel pharmaceuticals for therapeutic development
and for diagnostics for use in treating human disease. Employee acknowledges and agrees that the Company’s special competence in
the industry is critical to its growth. The Company’s competitive advantage and growth further depend on its exclusive possession
of certain proprietary information concerning the Company’s operations, processes, research, discoveries, methods and accumulated
experience incidental to the Company’s services and products, including, without limitation, those matters not generally known
to the public or to the industry in which the Company is or may be engaged and which pertain to research and development, advertising,
promotions, market research, concepts, ideas, and trade secrets (collectively “Confidential Information”). Employee desires
to be employed by the Company and the Company desires to employ Employee subject, however, to the terms and conditions set forth in this
Agreement.

 

4.2
Inventions Defined. For purposes of this Agreement, the term “Inventions” means discoveries, data, concepts and ideas,
whether or not patentable, and without limitation: processes, methods, formulas and techniques as well as improvements and know-how related
thereto, arising out of or related to any present or prospective activities of the Company in which Employee is engaged or aware as a
result or consequence of Employee’s employment by the Company.

 

4.3
Covenants, Agreements, Representations and Warranties by Employee. In consideration of the fact that Employee’s work as
an employee of Company will bring Employee into close contact with many confidential affairs of the Company and its affiliates, including
matters of a business nature, such as information about costs, profits, markets, sales, and any other information not readily available
to the public, and plans for future commercial and technological developments, Employee, for good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, covenants, agrees, represents and warrants that:

 

	 	a.	All
    of the Confidential Information is a valuable asset of the Company and, at all times, will be made and remain the Company’s
    sole and exclusive property.
	 	 	 
	 	b.	Employee
    shall, at all times, hold the Confidential Information as secret.
	 	 	 
	 	c.	Employee
    shall neither directly nor indirectly exploit or permit the exploitation, copying or summarizing of any of the Confidential Information,
    except in the performance of Employee’s duties for the Company or as the Company otherwise directs.
	 	 	 
	 	d.	During
    the term of Employee’s employment by the Company and after termination of that employment with or without cause, Employee shall
    not, directly or indirectly, individually or in combination or association with any other person or entity, divulge or disclose to
    any third party any of the Confidential Information without, in each instance, the prior written consent of the Company.
	 	 	 
	 	e.	During
    the term of Employee’s employment by the Company and for the period of one year following termination of that employment with
    or without cause, Employee shall promptly disclose in writing to the Company all inventions conceived or made by Employee, either
    solely or in concert with others.
	 	 	 
	 	f.	Employee
    hereby assigns to the Company all of Employee’s right, title, and interest to all such inventions and to applications for United
    States and/or foreign letters patents granted on such inventions.
	 	 	 
	 	g.	All
    inventions made or conceived by Employee shall be the Company’s sole and exclusive property.

 

    	2

     

    

 

	 	h.	Company
    shall own, and Employee hereby transfers and assigns to it, all rights of every kind and character, in perpetuity, in and to any
    material and/or ideas written, suggested, or submitted by Employee hereunder which relate to the intellectual property owned by the
    Company and all other results and proceeds of Employee’s services hereunder, whether the same consists of scientific, technical,
    clinical, engineering or any other form of works, themes, ideas, creations, products, or compositions (collectively, “Employee
    Inventions”). Employee agrees to execute and deliver to Company such assignments or other instruments as Company may require
    from time to time to evidence its ownership of the Employee Inventions, including, but not limited to, obtaining and defending letters
    patents in any and all countries and to vest title in such inventions in the Company or its assigns.
	 	 	 
	 	i.	Third
    Party Information. Employee understands, in addition, that the Company has received and in the future will receive from third
    parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s
    part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
    and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company
    personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work
    for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing.
	 	 	 
	 	j.	Upon
    termination of Employee’s employment with the Company with or without cause, Employee shall immediately deliver to the Company
    all notebooks, reports, formulae, notes, manuals and other documents, whether in hard copy or electronic, reflecting the Confidential
    Information and all other materials furnished to or acquired by Employee as a result of or during Employee’s employment by
    the Company.
	 	 	 
	 	k.	In
    the event that any of the restrictions and limitations of this Paragraph 4.3 shall be deemed to exceed the time or activity limitations
    permitted by applicable law, then such provisions shall be reformed to the maximum extent permitted by applicable law.
	 	 	 
	 	l.	Employee’s
    representations and warranties herein shall be revived continuously during the period of Employee’s employment by the Company.

 

5.
Non-Compete

 

5.1
In consideration of the salary and the bonus indicated in Paragraph 2.1 and 2.2, infra, the Employee further acknowledges and
agrees that following termination of employment with Company for any reason, the Employee shall not work as a competitor, or for a competitor,
of the Company for a period not to exceed one (1) year.

 

5.2
The Employee further acknowledges and agrees that following termination of employment with Company for any reason, the Employee shall
not hire or attempt to hire any current employees of Company.

 

6.
Laws

 

This
Agreement shall be construed and enforced pursuant to the laws of the state of Maryland.

 

7.
Independent Legal Advice

 

The
Employee acknowledges that the Company has provided the Employee with a reasonable opportunity to obtain independent legal
advice with respect to this agreement, and that either:

 

	 	(a)	The
    Employee has had such independent legal advice prior to executing this agreement, or;

 

	 	(b)	The
    Employee has willingly chosen not to obtain such advice and to execute this agreement without having obtained such advice.

 

    	3

     

    

 

8.
Miscellaneous Provisions

 

8.1
Severability. If any provision or clause of this Agreement is held to be invalid by a court of competent jurisdiction, then such
provision or clause shall be severed and shall not affect the validity and enforceability of any other provision of this Agreement.

 

8.2
Modification. This Agreement may not be amended or modified except in a writing signed by each of the parties hereto.

 

8.3
Breach. If Employee defaults in or breaches any of the covenants, agreements, representations or warranties described in this
Agreement, Employee shall be liable to and pay the Company its court costs and reasonable attorneys’ fees incurred in enforcing
such covenants, agreements, representations and warranties.

 

8.4
Injunctive Relief. It is acknowledged that the rights of Company under this Agreement are of a special, unique, and intellectual
character which gives them a peculiar value, and that a breach of any provision of this Agreement, will cause Company irreparable injury
and damage which cannot be reasonably or adequately compensated in damages in an action at law. Accordingly, without limiting any right
or remedy, Employee specifically agrees that Company shall be entitled to seek injunctive relief to enforce and protect its rights under
this Agreement.

 

8.5
Notices. All notices, requests, consents and other communications required or permitted to be given hereunder shall be in writing
and shall be deemed to have been duly given if delivered personally, mailed first-class, postage prepaid, or via electronic mail
as follows: If to Employee: 5910 River Glen Court, Carmichael, CA 95608; If to Company: 1 Research
Court, Suite 450, Rockville, MD 20850.

 

8.6
This Agreement sets forth the entire understanding of the parties hereto and supersedes all prior agreements, whether oral or written,
regarding the subject matter hereof.

 

IN
WITNESS WHEREOF, the Company has caused this agreement to be executed by its duly authorized officer and the Employee has set his
hand as of the date first above written.

 

	SIGNED:

 

	/s/
    Theodore Phillips	 	July
    29, 2014	 
	Theodore
    L. Phillips, M.D.	 	Date	 
	 	 	 	 
	SIGNED
    ON BEHALF OF COMPANY:	 	 	 
	 	 	 	 
	/s/
    Anatoly Dritschilo	 	July
    30, 2014	 
	Anatoly
    Dritschilo	 	Date	 
	Chief
    Executive Officer	 	 	 
	Shuttle
    Pharmaceuticals, LLC	 	 	 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]